Finch Therapeutics Group, Inc.
FNCHDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Full Spectrum Microbiota
Clostridium Difficile Infection Recurrence
CP101
Clostridium Difficile Infection
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Full Spectrum Microbiota | Phase 2 | Clostridium Difficile Infection Recurrence | - | - |
CP101 | Phase 2 | Clostridium Difficile Infection | - | - |
Frequently asked questions
What is in Finch Therapeutics Group, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Finch Therapeutics Group, Inc.'s (FNCH) pipeline across Phase 2. Its lead program is Full Spectrum Microbiota (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Finch Therapeutics Group, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Finch Therapeutics Group, Inc. (FNCH) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track FNCH biotech catalysts?→
Add FNCH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Finch Therapeutics Group, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.